Compare Global X Cybersecurity (BUG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cybersecurity vs Incyte Corporation — how do they compare? Global X Cybersecurity trades at $42.48, while Incyte Corporation trades at $112.62 (market cap $22.82B). The key difference: Global X Cybersecurity is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| BUG | INCY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $41.99 | $118.52 |
52-Week Low | $23.30 | $67.38 |
Market Cap | — | $22.82B |
Enterprise Value | — | $18.85B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
